Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

300%

3 of 1 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04804007Phase 2Recruiting

Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT

Role: lead

NCT02619253Phase 1Completed

Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma

Role: lead

NCT03737123Phase 2Terminated

Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Role: lead

NCT02689219Phase 2Terminated

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

Role: lead

All 4 trials loaded